(5Z)-(9S,11S)-11-fluoro-13-hydroxy-9-(tetrahydropyran-2-yloxy)-14,15,16,17,18,19,20-heptanor-5-prostenoic acid isopropyl ester | 208114-25-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (5Z)-(9S,11S)-11-fluoro-13-hydroxy-9-(tetrahydropyran-2-yloxy)-14,15,16,17,18,19,20-heptanor-5-prostenoic acid isopropyl ester
• 英文别名: (Z)-isopropyl 7-((1R,2S,3S,5S)-3-fluoro-2-(hydroxymethyl)-5-(tetrahydro-2H-pyran-2-yloxy)cyclopentyl)hept-5-enoate；propan-2-yl (Z)-7-[(1R,2S,3S,5S)-3-fluoro-2-(hydroxymethyl)-5-(oxan-2-yloxy)cyclopentyl]hept-5-enoate
• CAS: 208114-25-4
• 化学式: C₂₁H₃₅FO₅
• 分子量: 386.504
• InChiKey: MLRRBKGINFORAI-GJHGIRJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (5Z)-(9S,11S)-11-fluoro-13-hydroxy-9-(tetrahydropyran-2-yloxy)-14,15,16,17,18,19,20-heptanor-5-prostenoic acid isopropyl ester 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 生成 (5Z,13E)-(9S,11S)-11-fluoro-15-(2-indanyl)-15-oxo-9-(tetrahydropyran-2-yloxy)-16,17,18,19,20-pentanor-5,13-prostadienoic acid isopropyl ester
  参考文献：
  名称：

  Griffin, Brenda W.; Klimko, Peter; Crider, Julie Y., Journal of Pharmacology and Experimental Therapeutics, 1999, vol. 290, # 3, p. 1278 - 1284

  摘要：

  DOI：
• 作为产物：
  描述：

  (5Z)-(9S,11S)-13-(t-butyldiphenylsiloxy)-11-fluoro-9-(tetrahydropyran-2-yloxy)-14,15,16,17,18,19,20-heptanor-5-prostenoic acid isopropyl ester 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以85%的产率得到(5Z)-(9S,11S)-11-fluoro-13-hydroxy-9-(tetrahydropyran-2-yloxy)-14,15,16,17,18,19,20-heptanor-5-prostenoic acid isopropyl ester
  参考文献：
  名称：

  11-halo prostaglandins for the treatment of glaucoma or ocular hypertension

  摘要：

  一种治疗青光眼或眼压增高的方法，包括向患者施用公式I的化合物的药物有效量。

  公开号：

  US06353000B1

文献信息

• 11&bgr;-fluoro 15&bgr;-hydroxy PGF2&agr; analogs as FP receptor antagonists
  申请人：Alcon Manufacturing, Ltd.

  公开号：US06441033B1

  公开（公告）日：2002-08-27

  Methods and compositions for the antagonism of FP receptor-mediated biological responses are disclosed.

  本发明揭示了用于拮抗FP受体介导的生物反应的方法和组合物。
• PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS
  申请人：Barta Nancy S.

  公开号：US20090221654A1

  公开（公告）日：2009-09-03

  A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

  一种具有对EP受体选择性的前列腺素类似物，表现出EP激动剂活性，可用于扩大造血干细胞群体或治疗或预防流感、骨折、骨病、青光眼、眼压增高、痛经、早产、免疫障碍、骨质疏松症、哮喘、过敏、男性性功能障碍、女性性功能障碍、牙周病、胃溃疡、肾脏疾病或其他EP受体介导的疾病。
• Prostaglandin E1 and E2 analogs for the treatment of various medical conditions
  申请人：Cayman Chemical Company, Incorporated

  公开号：US08063240B2

  公开（公告）日：2011-11-22

  A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.

  一种前列腺素类似物，具有选择性作用于EP受体并表现出EP激动剂活性，可用于扩大造血干细胞群体或治疗或预防流感、骨折、骨疾病、青光眼、眼压增高、痛经、早产、免疫障碍、骨质疏松症、哮喘、过敏、男性性功能障碍、女性性功能障碍、牙周病、胃溃疡、肾脏疾病或其他EP受体介导的疾病。
• US8063240B2
  申请人：——

  公开号：US8063240B2

  公开（公告）日：2011-11-22
• [EN] PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS<br/>[FR] ANALOGUES DE PROSTAGLANDINE E1 ET E2 POUR LE TRAITEMENT DE DIVERSES AFFECTIONS MÉDICALES
  申请人：CAYMAN CHEM CO

  公开号：WO2009065070A2

  公开（公告）日：2009-05-22

  A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.